Pulmonary alveolar proteinosis (PAP) is a syndrome characterized by the accumulation of
alveolar surfactant and dysfunction of alveolar macrophages. PAP results in progressive …

Pulmonary alveolar proteinosis – current and future therapeu... : Current Opinion in Pulmonary
Medicine Pulmonary alveolar proteinosis – current and future therapeutical strategies : Current …

Autoimmune pulmonary alveolar proteinosis (PAP) is a rare disease characterized by
myeloid cell dysfunction, abnormal pulmonary surfactant accumulation, and innate immune …

Background Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare disease
characterized by progressive surfactant accumulation and hypoxemia. It is caused by …

Rationale Whole lung lavage (WLL) is a widely accepted palliative treatment for
autoimmune pulmonary alveolar proteinosis (aPAP) but does not correct myeloid cell …

Pulmonary alveolar proteinosis (PAP) is a devastating lung disease caused by abnormal
surfactant homeostasis, with a prevalence of 6–7 cases per million population worldwide …

Pulmonary alveolar proteinosis (PAP) is a rare respiratory syndrome characterised by the
accumulation of surfactant lipoproteins within the alveoli. According to various pathogenetic …

Background Pulmonary alveolar proteinosis (PAP) is a rare syndrome caused by several
distinct diseases leading to progressive dyspnoea, hypoxaemia, risk of respiratory failure …

Pulmonary alveolar proteinosis (PAP) is a rare pulmonary disorder that is characterized by
the abnormal accumulation of surfactant within the alveoli. Alveolar macrophages (AMs) …

Pulmonary alveolar proteinosis (PAP) is a rare pulmonary surfactant homeostasis disorder
resulting in buildup of lipo-proteinaceous material within the alveoli. PAP is classified as …